Castle Biosciences, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for CSTL, updated each market day.
CSTL AI Sentiment
AI predicts Castle Biosciences, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Castle Biosciences, Inc. Common Stock
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Sector
Exchange
Market Cap
$709,834,459
Cap Tier
Employees
883
Headquarters
FRIENDSWOOD, TX
Listed Since
July 25, 2019
CSTL Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CSTL Volatility
Castle Biosciences, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
